disease

cte

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about cte: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2Connections
6Hypotheses
25Analyses
1Outgoing
1Incoming
20Experiments
17Debates

No summary available yet. View on Wiki →

No AI portrait yet

Wiki Pages (20)

Knowledge base pages for this entity

Tau Strain Diversity and Conformational Templating in Tauopathies

mechanism · 4415 words

Traumatic Brain Injury and Neurodegeneration Pathway

mechanism · 4171 words

Tauopathies

mechanism · 4072 words

Experiment Prioritization Index — Neurodegeneration

general · 3915 words

Frontotemporal Dementia

disease · 3759 words

Pathway Diagram

flowchart TD
    CTE["CTE"] -->|"phosphorylates"| TAU["TAU"]
    TAU["TAU"] -->|"associated with"| NEURODEGENERATION["NEURODEGENERATION"]
    TAU["TAU"] -->|"activates"| NEURODEGENERATION["NEURODEGENERATION"]
    TAU["TAU"] -->|"associated with"| ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
    TAU["TAU"] -->|"associated with"| TAUOPATHY["TAUOPATHY"]
    style CTE fill:#006494,stroke:#333,color:#e0e0e0
    style TAU fill:#4a1a6b,stroke:#333,color:#e0e0e0
    style NEURODEGENERATION fill:#5d2900,stroke:#333,color:#e0e0e0
    style ALZHEIMER_S_DISEASE fill:#4a1a6b,stroke:#333,color:#e0e0e0
    style TAUOPATHY fill:#4a1a6b,stroke:#333,color:#e0e0e0

Outgoing (1)

TargetRelationTypeStr
TAUphosphorylatesentity0.60

Incoming (1)

SourceRelationTypeStr
APOEco_associated_withgene0.30

Targeting Hypotheses (6)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Smartphone-Detected Motor Variability Correction 0.742 neurodegeneration Digital biomarkers and AI-driven early d
TFAM overexpression creates mitochondrial donor-recipient gr 0.725 neurodegeneration Mitochondrial transfer between astrocyte
Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cro 0.642 neurodegeneration What are the mechanisms by which gut mic
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis 0.590 neurodegeneration What are the mechanisms by which gut mic
APOE4 Isoform Correction via Lipidation Enhancement as CTE R 0.552 neurodegeneration What genetic risk factors predispose ind
H63D HFE Genotype-Guided Iron Chelation Therapy for Subset-S 0.550 - Ferroptosis in ALS and motor neuron dise

Mentioning Analyses (25)

Scientific analyses that reference this entity

How does Alectinib, a kinase inhibitor, achieve high-affinity binding to complem

neuroinflammation | 2026-04-16 | 5 hypotheses Top: 0.587

What are the precise temporal dynamics of astrocyte ketone production decline du

neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.808

How does engineered C. butyricum cross the blood-brain barrier to directly bind

neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.703

Why does PRKN-mediated mitophagy, typically protective, cause harmful mitochondr

neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.455

What genetic risk factors predispose individuals to developing CTE following rep

neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.552

Experiments (20)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
N-of-1 Clinical Trial Design for CBS/PSP clinical ALS 0.400 0.50 human proposed $5,460,000
Experiment Scoring Methodology clinical Neurodegeneration 0.400 0.50 human proposed $5,460,000
Neural Oscillation Dysfunction Validation in Parkinson's Disease clinical Parkinson's Disease 0.400 0.50 human proposed $5,460,000
Levodopa Response Determinants in PSP — Biomarker-Guided Prediction St clinical Neurodegeneration 0.400 0.50 human proposed $5,460,000
Prodromal Parkinson's Disease Biomarker Development — Early Detection clinical Parkinson's Disease 0.400 0.50 human proposed $6,550,000
Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for P clinical Parkinson's Disease 0.400 0.50 human proposed $5,460,000
Parkinson's Disease Subtype Classification — Precision Medicine Approa clinical Parkinson's Disease 0.400 0.50 human proposed $6,550,000
Alpha-Synuclein Seed Amplification Assay Validation clinical Parkinson's Disease 0.400 0.50 human proposed $7,500,000
DLB Treatment Response Biomarkers — Predicting Cholinesterase Inhibito clinical Neurodegeneration 0.400 0.50 human proposed $6,550,000
Levodopa-Induced Dyskinesias Mechanism — Experiment Design validation Neurodegeneration 0.400 0.50 human proposed $2,280,000
Wilson Disease Neurodegeneration: Mechanism and Therapeutic Response clinical Neurodegeneration 0.400 0.50 human proposed $7,500,000
Selective Neuronal Vulnerability to Aging — Mapping Why Specific Neuro validation Neurodegeneration 0.400 0.50 human proposed $3,000,000
Exercise-BDNF-Mitophagy Biomarker Study in PD clinical Parkinson's Disease 0.400 0.50 human proposed $6,550,000
GLP-1 Agonist Neuroprotection Mechanism in PD clinical Parkinson's Disease 0.400 0.50 human proposed $6,550,000
Synaptic Mitochondrial Resilience Enhancement for Parkinson's Disease validation Parkinson's Disease 0.400 0.50 human proposed $2,730,000
Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in Parkinson' clinical Parkinson's Disease 0.400 0.50 human proposed $5,460,000
Cytochrome Therapeutics clinical Parkinson's Disease 0.400 0.50 human proposed $5,460,000
Ferroptosis Validation in Parkinson's Disease clinical Parkinson's Disease 0.400 0.50 human proposed $6,550,000
Selective Vulnerability of Dopaminergic Neurons — Mechanism and Protec validation Neurodegeneration 0.400 0.50 cell_line proposed $160,000
s:** - Test MCU overexpression specifically in layer II neurons in hea falsification Neurodegeneration 0.400 0.50 mouse proposed $200,000

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (17)

Multi-agent debates referencing this entity

The abstract reports that Alectinib binds C1q with high affinity, but this is me

closed · Rounds: 4 · Score: 0.94 · 2026-04-16

PGC-1α is known to enhance mitochondrial function and antioxidant responses, yet

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

The finding that Mertk/Axl deficiency increases viral susceptibility contradicts

closed · Rounds: 4 · Score: 0.74 · 2026-04-16

The abstract explicitly states the critical need to identify genetic risk factor

closed · Rounds: 4 · Score: 0.58 · 2026-04-16

The observation that salsalate and diflunisal decrease both AD and TBI incidence

closed · Rounds: 4 · Score: 0.95 · 2026-04-16

The abstract claims C. butyricum-GLP-1 crosses the BBB and binds to GLP-1 recept

closed · Rounds: 4 · Score: 0.95 · 2026-04-15

The abstract reveals an unexpected contradiction where PRKN activation, normally

closed · Rounds: 4 · Score: 0.91 · 2026-04-15

The study shows dramatic functional recovery and muscle re-innervation after cyt

closed · Rounds: 4 · Score: 0.85 · 2026-04-15

The finding that Mertk/Axl deficiency increases viral susceptibility contradicts

closed · Rounds: 4 · Score: 0.75 · 2026-04-15

The debate identified a critical therapeutic window when astrocytic ketone produ

closed · Rounds: 4 · Score: 0.85 · 2026-04-15